مصادر الصور
-
(1-2) Mulrow CD. Rationale for systematic reviews. BMJ. 1994 Sep 3;309(6954):597–9. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2541393/?page=1;
-
(1-3) Ranibizumab and pegaptanib for the treatment of age- related macular degeneration: a systematic review and economic evaluation. NICE 2006. Available at: http://www.nice.org.uk/nicemedia/live/11700/34991/34991.pdf.
-
(3-1) Carpenter D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton University Press, 2010.
-
(3-2) Schwartz LM, Woloshin S, Welch HG. Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials. Ann Intern Med. 2009 Apr 21;150(8):516–27. Available at: http://dartmed.dartmouth.edu/spring08/pdf/disc_drugs_we/lunesta_box.pdf.
-
(4-1) Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART) study. The Lancet. 2005 Oct;366(9493): 1261-2.
-
(4-3) Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. The Lancet. 2005;365(9454):176–86. Available at: http://apps.who.int/rhl/Lancet_365-9454.pdf.
-
(6-1) Moynihan R. The making of a disease: female sexual dysfunction. BMJ. 2003;326(7379):45–47. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124933/table/TN0x95f06b0.0x98eca30/.
-
(6-6) Drug Industry Document Archive [Internet]. Available at: http://dida.library.ucsf.edu/pdf/vou38h10.
-
(7-1) 15 August 2012, http://uk.finance.yahoo.com/echarts?s=GSK.L#symbol=GSK.L;range=1y.
